| Company/Division name | Abbott |
| Parent company | Abbott |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2025 |
| Year reshoring implemented or to be implemented: | 2028 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 500 |
| State(s) reshored to: | GA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Medical Equipment & Supplies |
| Product(s) reshored | transfusion diagnostics manufacturing |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Manufacturing/engineering joint innovation (R&D), Proximity to customers/market |
